Lightnews — Scholar-powered news

LightNews

Ulrike Harjes

@ulrikeharjes.bsky.social

1.9K followers 1.3K following 13 posts

PhD, Senior editor for oncology at Nature Medicine @natmedicine.bsky.social. Previously at Nature Reviews Cancer. Views are my own.

Posts Media Videos Starter Packs

Ulrike Harjes @ulrikeharjes.bsky.social · Jun 27

"Antigen-presenting mast cells are new players in breast cancer immunotherapy" by #NachoMelero, a N&V on "Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial" by Shao et al, : www.nature.com/articles/s41... #Immunotherapy

Antigen-presenting mast cells are new players in breast cancer immunotherapy - Nature Medicine

A new study identifies a novel subset of mast cells that cross-present tumor antigens in patients triple-negative breast cancer — and a pilot clinical trial shows how these can be exploited in immunot...

Ulrike Harjes @ulrikeharjes.bsky.social · Jun 27

Mobilizing antigen-presenting #MastCells in anti-PD-1-refractory triple-negative #BreastCancer: a phase 2 trial
by Song-Yang WuXi JinYi-Zhou Jiang #TNBC www.nature.com/articles/s41...

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial - Nature Medicine

In a reverse-translational study followed by a clinical trial, the targeting of antigen-presenting mast cells was identified as a therapeutic approach to overcome anti-PD-1 resistance in patients with...

Ulrike Harjes @ulrikeharjes.bsky.social · May 5

To celebrate our 30th anniversary, Nature Medicine has commissioned 'Turning points' articles, in which researchers discuss the impact of their scientific discovery that was published around 30 yrs ago. Read this one: PD-L1 and the dawn of modern cancer immunotherapy www.nature.com/articles/s41...

PD-L1 and the dawn of modern cancer immunotherapy - Nature Medicine

Lieping Chen describes how his discoveries with PD-L1 yielded life-saving treatments for several cancers.

Reposted by Ulrike Harjes

Springer Nature @springernature.com · May 5

After a boom in microbiome research over the past decade, the field’s next step is finding wider clinical applications for their results. Researchers explore how clinical microbiome research has evolved, the opportunities for the field and the challenges it faces in this review.

#medsky 🩺⚕️

Clinical translation of microbiome research - Nature Medicine

This Review summarizes recent and compelling examples of microbiome-based interventions that are ripe for clinical adoption while also discussing the challenges and opportunities facing the field.

Reposted by Ulrike Harjes

Prof Tom John @drtomjohn.bsky.social · Mar 19

Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine

Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...

Reposted by Ulrike Harjes

Saheli Sadanand @sahelisadanand.bsky.social · Apr 1

🧵(1/2) NEW #NatureMedicine #immunotherapy trial -- led & conducted by #NIH researchers. It shows that neoantigen-specific tumor-infiltrating lymphocytes elicit responses in patients w/ treatment-refractory, MMR proficient #GI cancers #OncSky #MedSky www.nature.com/articles/s41...

Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial - Nature Medicine

In an iterative phase 2 trial, patients with metastatic, treatment-refractory, mismatch repair proficient gastrointestinal cancers had responses to neoantigen-reactive tumor-infiltrating lymphocytes b...

Reposted by Ulrike Harjes

Magdalena Skipper @magdalenaskipper.bsky.social · Apr 4

Take Nature’s poll -
the new administration is reshaping the research landscape in the United States in profound ways.

What do you think of all the changes?

@nature.com

www.nature.com/articles/d41...

Take Nature’s poll: How will Trump’s policies affect US science?

The new administration is reshaping the research landscape in the United States in profound ways. What do you think of all the changes?

Reposted by Ulrike Harjes

Springer Nature @springernature.com · Jan 29

Find all Springer Nature journal and imprint accounts on Bluesky ⬇️.

Reposted by Ulrike Harjes

Saad Z. Usmani, MD @szusmani.bsky.social · Feb 6

Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky

@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social

www.nature.com/articles/s41...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine

In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...

Ulrike Harjes @ulrikeharjes.bsky.social · Feb 6

New out in #NatureMedicine: In the ph 3 #CEPHEUS trial, #daratumumab + bortezomib, lenalidomide & dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred newly diagnosed #MultipleMyeloma showed deeper & more durable increase in #MRD responses vs VRd. www.nature.com/articles/s41...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine

In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...

Reposted by Ulrike Harjes

Francesca Cesari @francesari.bsky.social · Jan 27

A study in Nature confirms that the phenomenon of mitochondrial transfer can occur bidirectionally between cytotoxic T cells and cancer cells within the tumour microenvironment. This leads to senescence of the T cells and impaired antitumour immunity.
www.nature.com/articles/s41... 🧪

Immune evasion through mitochondrial transfer in the tumour microenvironment - Nature

Mitochondria with mutations in their DNA from cancer cells can be transferred to T cells in the tumour microenvironment, which leads to T cell dysfunction and impaired antitumour immunity.

Ulrike Harjes @ulrikeharjes.bsky.social · Jan 27

New out in #NatureMedicine & at #ASCOGI: In the practice-changing #BREAKWATER ph3 trial, encorafenib, cetuximab & mFOLFOX6 vs investigator’s choice of CT w/wo bev in BRAF V600E mCRC led to improved ORR, w/ PFS still maturing.
Congrats to @skopetz.bsky.social et al!
www.nature.com/articles/s41...

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - Nature Medicine

As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF inhibitor encorafenib,...

Ulrike Harjes @ulrikeharjes.bsky.social · Jan 24

New out in #NatureMedicine: A phase 1 trial shows that the size of #CTC clusters (which can promote metastatic spread) can be reduced by treatment with the Na+/K+ ATPase inhibitor #digoxin in patients with metastatic #BreastCancer. By Nicola Aceto et al.
www.nature.com/articles/s41...

Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial - Nature Medicine

This proof-of-concept phase 1 trial shows that the size of circulating tumor cell clusters (which can promote metastatic spread) can be reduced by treatment with the Na+/K+ ATPase inhibitor digoxin in...

Reposted by Ulrike Harjes

Nature @nature.com · Jan 14

The research community has flocked to the social-media platform Bluesky.

Tell us about your experience
https://go.nature.com/42fihQG

Has Bluesky replaced X for scientists? Take Nature’s poll

The research community has flocked to the social-media platform Bluesky. Tell us about your experience.

Reposted by Ulrike Harjes

Gregory Riely @rielymd.bsky.social · Jan 6

Overview of molecular characteristics of pancreatic cancer from @mskcancercenter.bsky.social @mskdeptofmed.bsky.social with useful data. Reminder that KRAS is 95% of pancreatic cancer (~1% G12C), 10% have germline pathogenic alterations (e.g. BRCA1/2, ATM, PALB2). www.nature.com/articles/s41...

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival - Nature Medicine

Analyses of clinical and genomic data from a cohort of 2,336 patients with pancreatic adenocarcinoma find that KRAS dosage gains are a hallmark of disease progression and are predictive of poor outcom...

Reposted by Ulrike Harjes

lorenzorighetto.bsky.social @lorenzorighetto.bsky.social · Jan 7

Using multiple data sets, a machine learning model using routine blood and clinical data is shown to be predictive of patient response to immune checkpoint inhibitor therapy, across cancer types and outperforming standard biomarkers

www.nature.com/articles/s41...

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data - Nature Medicine

Using multiple datasets from real-world evidence and completed trials, a machine learning model using routine blood and clinical data is shown to be predictive of patient response to immune checkpoint...

Reposted by Ulrike Harjes

Saheli Sadanand @sahelisadanand.bsky.social · Jan 7

🌟 NEW in #NatureMedicine: Repeat infusions of B7-H3 #CARTcells were safe in children with diffuse intrinsic pontine glioma (#DIPG). Median OS = 19.8 months vs historical OS = 11 months. 3 patients alive 40 months post-diagnosis! @nickvitanza.bsky.social #OncSky www.nature.com/articles/s41...

Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial - Nature Medicine

In the final report of a phase 1 trial evaluating intracerebroventricular B7-H3-targeting CAR T cells in children and young adults with diffuse intrinsic pontine glioma, repeated intracranial infusion...

Ulrike Harjes @ulrikeharjes.bsky.social · Jan 6

New out in #NatureMedicine @natureportfolio.bsky.social :

Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations

by Qi Long & Ravi B. Parikh et al
#MachineLearning #Oncology

www.nature.com/articles/s41...

Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations - Nature Medicine

Machine-learning-based and population-level electronic health record data–based emulation of landmark phase 3 randomized controlled trials (RCTs) in oncology across a range of cancer and risk types sh...

Reposted by Ulrike Harjes

Gerry Hanna @gerryhanna.bsky.social · Dec 13

What trials will shape medicine in 2025?

@oncodaily.bsky.social @cancertrialsie.bsky.social

@natureportfolio.bsky.social has the answer.

Great to feature a trial on radionuclides featuring as well a number of other cancer related studies

www.nature.com/articles/s41...

Eleven clinical trials that will shape medicine in 2025 - Nature Medicine

Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health.

Ulrike Harjes @ulrikeharjes.bsky.social · Dec 10

very cool study in Nature by @colindascheele.bsky.social from VIB-CCB, Leuven

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy - Nature

In three mouse models of breast cancer, we show reduced responses to neoadjuvant chemotherapy when treatment is initiated during the dioestrus stage, when compared with initiation during the oestrus s...

Ulrike Harjes @ulrikeharjes.bsky.social · Dec 6

I wonder if this could become a bsky starter pack..

Ulrike Harjes @ulrikeharjes.bsky.social · Dec 2

ICYMI: To celebrate 100+ years of the #WarburgEffect, editors from across Springer Nature put together a collection of clinical, translational and preclinical studies as well as commentaries of #CancerMetabolism research. www.nature.com/collections/... @natureportfolio.bsky.social

Cancer Metabolism 2.0

The field of cancer metabolism research is entering its 2nd century since the first description of the changes in metabolism of cancer cells by Otto Warburg ...

Ulrike Harjes @ulrikeharjes.bsky.social · Dec 2

ICYMI: In the dose escalation phase of the ongoing #LIBRA4Trial, patients with relapsed/refractory peripheral T cell #lymphoma were treated with #TRBC1 -targeted #CARTCellTherapy, showing limited toxicity and promising early clinical responses. #NatureMedicine www.nature.com/articles/s41...

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial - Nature Medicine

In the dose-escalation part of the ongoing phase 1/2 LIBRA4 trial, patients with relapsed/refractory peripheral T cell lymphoma received T cell antigen receptor beta-chain constant domain 1 (TRBC1)-ta...

Ulrike Harjes @ulrikeharjes.bsky.social · Nov 28

#NatureMedicine is recruiting! We are looking for an editor to champion the areas of #Metabolism, #Endocrinology and #WomensHealth. Located in NY or Shanghai. Apply by Dec 2nd! Reach out if you have questions. @natureportfolio.bsky.social springernature.wd3.myworkdayjobs.com/SpringerNatu...

Associate or Senior Editor, Nature Medicine (Metabolism, Endocrinology & Women’s Health)

Title: Associate or Senior Editor, Nature Medicine (Metabolism, Endocrinology & Women’s Health) Location(s): New York or Shanghai - Hybrid Working Application Deadline: December 1st 2024 About Spr...

springernature.wd3.myworkdayjobs.com

Reposted by Ulrike Harjes

Barbara Marte @barbmarte.bsky.social · Nov 28

new out in Nature www.nature.com/articles/s41... the phase 3 SONIA trial (NCT03425838)

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature

The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.